Vertex Pharmaceuticals Incorporated (VRTX)
Automate Your Wheel Strategy on VRTX
With Tiblio's Option Bot, you can configure your own wheel strategy including VRTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VRTX
- Rev/Share 45.8658
- Book/Share 67.7574
- PB 6.8717
- Debt/Equity 0.1059
- CurrentRatio 2.3618
- ROIC 0.1618
- MktCap 119378051012.0
- FreeCF/Share 13.0563
- PFCF 35.7719
- PE 32.3828
- Debt/Assets 0.0738
- DivYield 0
- ROE 0.2181
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | VRTX | Barclays | -- | Overweight | -- | $606 | Jan. 28, 2026 |
| Upgrade | VRTX | RBC Capital Mkts | Sector Perform | Outperform | -- | $546 | Jan. 22, 2026 |
| Upgrade | VRTX | Bernstein | Market Perform | Outperform | -- | -- | Jan. 12, 2026 |
| Resumed | VRTX | UBS | -- | Buy | -- | $535 | Jan. 7, 2026 |
| Upgrade | VRTX | Wolfe Research | Peer Perform | Outperform | -- | $548 | Jan. 6, 2026 |
| Upgrade | VRTX | Morgan Stanley | Equal Weight | Overweight | -- | $516 | Dec. 3, 2025 |
| Initiation | VRTX | Scotiabank | -- | Sector Outperform | -- | $495 | Nov. 13, 2025 |
| Upgrade | VRTX | Leerink Partners | Market Perform | Outperform | -- | $456 | Sept. 25, 2025 |
| Initiation | VRTX | Raymond James | -- | Market Perform | -- | -- | Sept. 3, 2025 |
| Upgrade | VRTX | Wells Fargo | Equal Weight | Overweight | -- | $460 | Aug. 6, 2025 |
News
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager
Published: February 02, 2026 by: PRNewsWire
Sentiment: Neutral
SHANGHAI, Feb. 2, 2026 /PRNewswire/ -- WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license and research service agreement with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) for an innovative trispecific T-cell Engager (TCE) for the treatment of B-cell mediated autoimmune diseases.
Read More
Wall Street Analysts Think Vertex (VRTX) Is a Good Investment: Is It?
Published: January 23, 2026 by: Zacks Investment Research
Sentiment: Neutral
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read More
Will Vertex (VRTX) Beat Estimates Again in Its Next Earnings Report?
Published: January 12, 2026 by: Zacks Investment Research
Sentiment: Positive
Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Published: January 07, 2026 by: Zacks Investment Research
Sentiment: Positive
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
The Best Stocks to Invest $1,000 in to Start the New Year Off Right
Published: January 01, 2026 by: The Motley Fool
Sentiment: Positive
Alphabet should continue to benefit from a strong AI tailwind in 2026. Vertex Pharmaceuticals has several growth drivers in the new year.
Read More
Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Momentum Stock
Published: December 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Read More
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Published: December 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Why Vertex Pharmaceuticals (VRTX) is a Top Momentum Stock for the Long-Term
Published: December 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Why Is Vertex (VRTX) Up 2.7% Since Last Earnings Report?
Published: December 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?
Read More
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Published: December 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Read More
Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock?
Published: December 03, 2025 by: Zacks Investment Research
Sentiment: Positive
VRTX rises 9.2% in three months but trails its industry as mixed new-drug sales and tightened 2025 guidance cloud near-term momentum.
Read More
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock
Published: December 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Published: November 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Columbia Contrarian Core Fund Q3 2025 Performance Review
Published: November 18, 2025 by: Seeking Alpha
Sentiment: Negative
The fund underperformed its benchmark, the Russell 1000 Index, during the third quarter. Videogame producer Electronic Art's was the top contributor during the period. Elevance Health was the top underperformer over the period.
Read More
3 Best Healthcare Stocks: Quant Strong Buys From Goldman's 'Alpha' List
Published: November 17, 2025 by: Seeking Alpha
Sentiment: Positive
The healthcare sector's renewed momentum offers fertile ground for investors wanting to outperform by picking the best stocks from the broader indexes. Goldman Sachs identified 29 healthcare stocks in the Russell 1000 universe with positive recent consensus revisions to 2026 EPS estimates and that trade at attractive valuations. Goldman sees "more opportunity for alpha than beta" as wide return dispersion and increasing M&A activity in healthcare may favor selected winners.
Read More
Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Healthcare Conference 2025 Transcript
Published: November 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Vertex Pharmaceuticals Incorporated ( VRTX ) UBS Global Healthcare Conference 2025 November 11, 2025 10:15 AM EST Company Participants Reshma Kewalramani - CEO, President & Director Conference Call Participants Dina Elmonshed Presentation Dina Elmonshed Good morning, everyone. My name is Dina Elmonshed, one of the U.S. biotech analysts here at UBS.
Read More
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Published: November 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
VRTX's new drugs deliver a mixed Q3 performance. Alyftrek sales surge.
Read More
Committee stocks on the move: Uber and Vertex Pharma
Published: November 04, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee discuss some of their stocks on the move today.
Read More
Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
VRTX tops Q3 earnings and revenue estimates on strong Trikafta and Alyftrek sales, but shares slip as Casgevy sales disappoint.
Read More
Vertex Pharmaceuticals Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Published: November 03, 2025 by: Benzinga
Sentiment: Positive
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will release earnings results for the first quarter, after the closing bell on Monday, Nov. 3.
Read More
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Strong Trikafta/Kaftrio demand, along with contributions from Alyftrek, Casgevy and Journavx, may have helped VRTX outperform in the third quarter.
Read More
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Read More
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
Published: October 17, 2025 by: Business Wire
Sentiment: Neutral
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential.
Read More
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
About Vertex Pharmaceuticals Incorporated (VRTX)
- IPO Date 1991-07-24
- Website https://www.vrtx.com
- Industry Biotechnology
- CEO Reshma Kewalramani
- Employees 6100